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Abstract 61 
Objective: Necrotising enterocolitis (NEC) is a devastating intestinal disease primarily affecting 62 
preterm infants. The underlying mechanisms are poorly understood: mothers own breast milk (MOM) 63 
is protective, possibly relating to human milk oligosaccharide (HMO) and infant gut microbiome 64 
interplay. We investigated the interaction between HMO profiles and infant gut microbiome 65 
development and its association with NEC. 66 
Design: We performed HMO profiling of MOM in a large cohort of infants with NEC (n=33) with 67 
matched controls (n=37). In a subset of 48 infants (14 NEC) we also performed longitudinal 68 
metagenomic sequencing of infant stool (n=644). 69 
Results: Concentration of a single HMO, disialyllacto-N-tetraose (DSLNT), was significantly lower 70 
in MOM received by NEC infants compared to controls. A MOM threshold level of 241 nmol/mL 71 
had a sensitivity and specificity of 0.9 for NEC. Metagenomic sequencing before NEC onset showed 72 
significantly lower relative abundance of Bifidobacterium longum and higher relative abundance of 73 
Enterobacter cloacae in infants with NEC. Longitudinal development of the microbiome was also 74 
impacted by low MOM DSLNT associated with reduced transition into preterm gut community types 75 
dominated by Bifidobacterium spp. and typically observed in older infants. Random forest analysis 76 
combining HMO and metagenome data before disease accurately classified 87.5% of infants as 77 
healthy or NEC.  78 
Conclusion: These results demonstrate the importance of HMOs and gut microbiome in preterm 79 
infant health and disease. The findings offer potential targets for biomarker development, disease risk 80 
stratification, and novel avenues for supplements that may prevent life-threatening disease. 81 
 82 
 83 
 84 
 85 
 86 
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1. What is already known about this subject? 87 
• Necrotising enterocolitis (NEC) is one of the leading causes of death in preterm infants 88 
• Maternal human milk oligosaccharides (HMOs) including disialyllacto-N-tetraose (DSLNT) 89 
have been associated with protection from NEC development 90 
• Differences in infant gut microbiome development have been linked to NEC and non-NEC 91 
infants, but the causative and protective organisms have not been determined 92 
 93 
2. What are the new findings? 94 
• We found for the first time that combined analysis of maternal HMOs and infant gut 95 
microbiome can predict NEC 96 
• A specific DSLNT threshold level of 241 nmol/mL had a sensitivity and specificity of 0.9 for 97 
NEC and infants receiving milk below this threshold showed abnormal microbiome 98 
development 99 
• Infants who developed NEC had significantly lower relative abundance of Bifidobacterium 100 
longum and significantly higher relative abundance of Enterobacter cloacae before disease 101 
diagnosis  102 
 103 
3. How might it impact on clinical practice in the foreseeable future? 104 
• Our findings demonstrate the importance of maternal HMOs and infant gut microbiome in 105 
preterm infants, providing targets for biomarker development, disease risk stratification, and 106 
novel avenues for supplementing the infant feed. 107 
  108 
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Introduction 109 
Necrotising enterocolitis (NEC) is an inflammation-mediated bowel condition that is a leading cause 110 
of death and serious morbidity in preterm infants born before 32 weeks gestation (1). The mechanisms 111 
underlying NEC development are poorly understood and the lack of specificity of symptoms and tests 112 
make diagnostic certainty difficult. Infants with NEC have enteral feeds stopped and are treated with 113 
broad-spectrum antibiotics, and may need surgery (2).  114 
Receipt of mother’s own breast milk (MOM) is the most protective factor against the development of 115 
NEC in preterm infants (3, 4). However, infants receiving MOM still develop NEC, suggesting the 116 
variable composition of nutrients and other components of breast milk may be important. Human 117 
milk oligosaccharides (HMOs) are structurally diverse, complex unconjugated sugars that are not 118 
usually present in artificial formula milk (5). HMOs are indigestible to the infant, reaching the lower 119 
gastrointestinal tract intact where they act as growth substrates (i.e. prebiotics) for specific bacteria, 120 
notably Bifidobacterium spp. thought key to infant health (6-8). HMOs may also protect from enteric 121 
organism blood stream infections due to anti-microbial activity (9), stimulate the immune system 122 
(10), enhance gut barrier function (11), and act as decoy receptors for pathogens (12). While >150 123 
HMOs have been described, the 19 most abundant represent >95% of the total HMO content (13). 124 
HMO profiles are specific to individual mothers and remain relatively stable during lactation (14). 125 
Presence of an active FUT2 gene, which is involved in the synthesis of α1-2-fucosylated 126 
oligosaccharides, is the main determinant of the HMO profile, termed maternal secretor status (15).  127 
Recent work has begun to elucidate the potential contribution of HMOs to preterm infant health. In a 128 
neonatal rat model, disialyllacto-N-tetraose (DSLNT), a non-fucosylated, but double-sialylated 129 
HMO, significantly reduced NEC development and improved NEC-associated mortality rate (16). 130 
An association of lower DSLNT concentration in MOM and subsequent higher risk of NEC onset in 131 
the infant has since been observed in preterm human studies (17-19). To date, these studies have 132 
included very small numbers of infants with NEC (between 4 and 8), with a broad range of NEC 133 
phenotypes. Thus, validation in a larger cohort is urgently needed.  134 
 
 6 
Altered gut microbiome development has been associated with NEC in preterm infants. While no 135 
specific causative microorganism has consistently been identified, studies have reported a higher 136 
relative abundance of Enterobacteriaceae, coupled to lower relative abundance of Bifidobacterium 137 
(20-23). Instability of the gut microbiome in NEC infants has also been reported in longitudinal 138 
studies, with more frequent transitions between different preterm gut community types (PGCT) in 139 
NEC (20). These findings were replicated at the site of disease in a study using formalin fixed paraffin 140 
embedded tissue from NEC infants matched to non-NEC controls (24). Previous microbiome studies 141 
have largely relied on 16S rRNA gene sequencing of the V4 region, which has limited resolution, 142 
especially for emerging key organisms of interest for preterm health (i.e., Klebsiella and Enterobacter 143 
would be classified together as Enterobacteriaceae). Metagenomics may overcome this and recent 144 
metagenomic data showed infants who developed NEC had higher relative abundance of Klebsiella 145 
and higher replication rates in all bacteria before disease onset (25). 146 
In this current study, we performed a combined analysis of maternal HMO profiles and longitudinal 147 
development of the infant stool/gut microbiome in a large cohort of preterm infants with NEC and 148 
healthy controls matched for gestation, birthweight and day of life. We then validated our results in 149 
an independent cohort using previously published HMO data (17). We hypothesised that differences 150 
in maternal HMO profiles and microbiome development may explain why some infants receiving 151 
MOM still develop NEC. 152 
  153 
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Methods 154 
Cohort  155 
This study included 77 preterm infants (born at <32 weeks gestation), who were born in or transferred 156 
to a single large tertiary level neonatal intensive care unit (NICU) in Newcastle upon Tyne, UK 157 
recruited to the SERVIS study (REC10/H0908/39) with written parental consent covering data and 158 
sample collection. 33 infants were diagnosed with definite NEC and 37 non-diseased controls were 159 
selected by identifying a healthy infant matched by gestation, birthweight, and having a MOM sample 160 
available at a corresponding day of life (DOL) (table 1). Detailed information on feeding and 161 
antibiotic use are included in online supplementary table 1 and online supplementary table 2. 162 
Diagnoses were made using an extensive combination of clinical, x-ray and histological findings and 163 
blindly agreed by two neonatal clinicians (JEB and NDE). Standard clinical protocols recommended 164 
the routine use of supplemental probiotics when more than 30mL/kg/day of MOM was tolerated for 165 
at least 1-2 days: all 33 NEC infants received MOM and 31 received probiotics. All 37 controls 166 
received probiotics. The probiotics administered were either LaBiNIC (Lactobacillus acidophilus, 167 
Bifidobacterium infantis and Bifidobacterium bifidum) or Infloran (L. acidophilus and B. bifidum).  168 
The median DOL of NEC diagnosis was 19 (interquartile range; IQR 14-35; table 1). A single MOM 169 
sample was analysed for each infant, as close to the onset of disease as possible, with control samples 170 
matched by day of life (DOL) (online supplementary figure 1). The median DOL of MOM from 171 
NEC cases was 18 (IQR 13-34) and from controls was also 18 (IQR 12-31). The DOL of the milk 172 
sample is the DOL received by the infant, and is not necessarily the same day as the mother expressed 173 
the milk due to standard practice that often involves milk storage. Metagenomic sequencing of stool 174 
samples (n = 644) was performed longitudinally on a subset of 48 infants (including 14 NEC; online 175 
supplementary figure 1). These infants were comparable to the full cohort (online supplementary 176 
table 3). 177 
 178 
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Full details of the HMO, metagenome, and statistical analysis are described in online supplementary 179 
methods. 180 
 181 
Human milk oligosaccharides analysis 182 
The absolute quantification for the 19 most abundant HMOs was determined by high-performance 183 
liquid chromatography (HPLC) following derivatization as per the protocol described by Bode et al. 184 
(26). Maternal secretor (presence of an active FUT2 gene) status was determined by presence or near-185 
absence of 2’FL in the breast milk analysed. 186 
 187 
Metagenomes 188 
DNA was extracted from ~0.1g of stool using the DNeasy PowerSoil Kit (QIAGEN) following the 189 
manufacturer’s protocol and sequencing was performed on the HiSeq X Ten (Illumina) with a read 190 
length of 150bp paired end reads. Processed fastq files were mapped against the MetaPhlan2 marker 191 
gene database (mpa_v20_m200) (27).  192 
 193 
Statistical analysis 194 
Statistical analysis of HMO profiles was performed using MetaboAnalyst 3.0 (28). For ordinations, 195 
HMO data was normalised by logarithmic transformation and 2000 random permutations were used 196 
to test the significance. Multivariate ROC curves were generated using linear Support Vector 197 
Machine (SVM) classification method coupled with Monte-Carlo cross validation (MCCV).  198 
Correlation between clinical variables and individual HMOs was tested by performing a multivariate 199 
adjusted linear model in R (version 3.6.3). HMO concentrations were normalised by log-200 
transformation prior to analysis and P values were adjusted applying the Benjamini & Hochberg 201 
correction (29).  202 
The cross-sectional cohort of stool samples collected from NEC infants before diagnosis and matched 203 
controls was analysed using MicrobiomeAnalyst (30, 31). Permutational multivariate analysis of 204 
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variance (PERMANOVA) was used to determine significance of Bray-Curtis principal coordinate 205 
analysis. MetagenomeSeq was used to assess differential abundance at the phyla and species level.  206 
DMM clusters samples on the basis of microbial community structure (32) and was used to determine 207 
the preterm gut community types (PGCTs) from all samples, as performed previously (33, 34). Five 208 
PGCT was found to be optimal, and these were ordered youngest (PGCT-1) to oldest (PGCT-5) based 209 
on the average DOL of samples within each PGCT. Analysis was performed at specific time windows, 210 
including only a single sample per infant in each time point.  211 
The association of various clinical variables on the HMO and metagenome profiles was tested by 212 
applying the function “adonis” of “vegan” (version 2.5-6) package (35) in R, based on Bray-Curtis 213 
dissimilarity and 10000 permutations. Each test was performed stepwise and P values were adjusted 214 
using Benjamini & Hochberg (29). 215 
Random Forest was used for comparing the performance of classification models built using matched 216 
cross-sectional datasets.  217 
 218 
Results  219 
Association of maternal HMOs and development of NEC in the infant 220 
MOM samples clustered according to maternal secretor status and secretor mothers had a higher total 221 
HMO concentration, a higher HMO Shannon diversity, and a significantly higher concentration of 222 
overall HMO-bound fucose (online supplementary figure 2). Thus, where relevant, we have 223 
stratified and adjusted for maternal secretor status in subsequent analyses. 224 
HMO profiles showed significant separation of NEC and control infants (figure 1a; 2000 225 
permutations, P < 0.001) and this was consistent when secretor and non-secretor samples were 226 
analysed separately (both P < 0.001; online supplementary figure 3a and 3b). Individually, of the 227 
19 HMOs quantified in this study, only DSLNT was significantly different between NEC and 228 
controls, with a lower concentration in NEC infants (adj. P < 0.001; figure 1b and 1c). No significant 229 
associations were found in the Shannon diversity of HMOs between NEC and matched controls for 230 
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the full cohort, or when stratified by maternal secretor status (all P > 0.05; online supplementary 231 
figure 4).  232 
Given that lower DSLNT was associated with NEC independent of secretor status, the utility of this 233 
HMO as a biomarker for NEC development was explored. Univariate ROC curve analysis determined 234 
that 241 nmol/mL (or 310.93 µg/mL) was the optimal DSLNT concentration in MOM for 235 
distinguishing NEC and control infants (figure 1c and 1d). At this threshold, the area under the curve 236 
(AUC) was 0.946 with a sensitivity of 0.9 and a specificity of 0.9, correctly identifying 91% of NEC 237 
infants (below threshold) and 86% of control healthy infants (above threshold).   238 
To test if integration of additional HMOs could improve the classification performance, multivariate 239 
ROC curves built on increasing number of HMOs were performed (online supplementary figure 240 
5a). Inclusion of 2 HMOs (the minimum in multivariate analysis) resulted in the optimal performance, 241 
with DSLNT being selected as a discriminatory feature in 100% of permutations (online 242 
supplementary figure 5b). 3FL and LNnT were the 2nd and 3rd most selected features, with a 243 
selection frequency of around 30%, being more abundant in cases of NEC. However, the integration 244 
of any additional HMOs to DSLNT in the multivariate model resulted in minimal improvement in 245 
performance compared to the univariate model using DSLNT only (AUC of 0.949 and 0.946, 246 
respectively).  247 
To validate the 241 nmol/mL threshold defined in the current study in an independent cohort, we 248 
analysed data from Autran et al. (2018) which contained 8 NEC and 40 matched control infants (17). 249 
Since this study included temporal sampling before disease, we selected the nearest milk sample to 250 
NEC onset for each infant and matched the control samples by sample DOL and included only 251 
DSLNT concentration. Using a DSLNT threshold of 241 nmol/mL, the MOM sample for 100% (8/8) 252 
NEC infants fell under the threshold, while 60% (24/40) control samples had a DSLNT concentration 253 
above 241 nmol/mL (online supplementary figure 5c).  254 
 255 
Analysis of HMO profiles stratified by NEC type 256 
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We compared medically managed NEC (NEC-M), where infants did not undergo surgery or die from 257 
NEC (i.e. had less severe disease), with NEC infants that underwent surgery (NEC-S). NEC-M and 258 
NEC-S clustered together and were distinct from matched controls (figure 2a; 2000 permutations, P 259 
< 0.001). Two HMOs were found to be significantly different, with DSLNT lower in MOM in both 260 
NEC-M (adj. P < 0.001) and NEC-S (adj. P < 0.001) compared to controls (figure 2b). In addition, 261 
LNnT in MOM was significantly lower in NEC-S in comparison to both NEC-M (adj. P = 0.0016) 262 
and matched controls (adj. P = 0.0423) (figure 2c).  263 
We subsequently investigated the potential association between DSLNT and LNnT concentrations 264 
and clinical variables by applying an adjusted linear model. DSLNT was negatively correlated to both 265 
disease types, with coefficients equal to -0.60 for NEC-M (adj. P < 0.001) and -0.67 for NEC-S (adj. 266 
P < 0.001) (figure 2d). However, LNnT was not associated with disease type following adjusted 267 
linear modelling (both adj. P > 0.05). DSLNT and LNnT were both significantly higher in secretor 268 
mothers (adj. P = 0.008, adj. P < 0.001, respectively). DSLNT in MOM also positively correlated to 269 
gestational age (adj. P = 0.008) and negatively to birthweight (adj. P = 0.008). Neither HMO 270 
correlated to sex, delivery mode, post-menstrual age, or DOL of the MOM sample (figure 2d and 271 
online supplementary figure 6).  272 
 273 
Association of infant gut microbiome and development of NEC  274 
We included stool microbiome data on a subset of infants with HMO data, where metagenomic 275 
sequencing data was available through an on-going independent study (the results of which are not 276 
yet published). This included 644 stool samples from 34 controls, and 14 NEC infants (online 277 
supplementary table 3). To overcome challenges of repeated measures and to compare results with 278 
existing published work, we first analysed one stool sample per infant closest to NEC onset (median 279 
of 3 days before NEC) and a corresponding control sample matched by DOL (online supplementary 280 
figure 1). This cross-sectional analysis showed NEC infants had significantly lower richness (P = 281 
0.027) but comparable Shannon diversity (P = 0.443; figure 3a). Bray-Curtis PCoA showed no 282 
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significant difference between the bacterial profiles of NEC and controls (PERMANOVA P = 0.182; 283 
figure 3b). Analysis at the phylum level showed significantly lower relative abundance of 284 
Actinobacteria (adj. P = 0.034) and higher relative abundance of Proteobacteria (adj. P = 0.034) in 285 
NEC infants (figure 3c). Correspondingly, at the species level, NEC infants had lower relative 286 
abundance of Bifidobacterium longum (adj. P = 0.012) and higher relative abundance of Enterobacter 287 
cloacae (adj. P = 0.012), compared to controls (figure 3d). 288 
 289 
Integrated analysis of HMO and bacterial profiles 290 
DMM clustering was used to determine preterm gut community types (PGCT) using species level 291 
data and five PCGTs was deemed optimal (figure 4a). PGCT-1 was characterised by high relative 292 
abundance of Staphylococcus spp. and Enterococcus faecalis, PGCT-2 had high Escherichia spp., 293 
PGCT-3 had high Klebsiella spp., and PGCT-4 and PGCT-5 had high Bifidobacterium spp. with B. 294 
breve notably high in PGCT-5. Using the PGCT clusters, we analysed the temporal transition of an 295 
infant’s gut microbiome over the first 70 days of life by defining distinct time points and including 296 
only one sample per infant at each time point. Based on the distribution of samples across all time 297 
points and all clusters, the temporal transition of the microbiome over the first 70 days of life was 298 
significantly different in infants in receipt of MOM below the DSLNT threshold of 241 nmol/ml 299 
compared to infants above the DSLNT threshold (χ2 test P < 0.001; figure 4b).  300 
The PGCTs were named according to the average age of samples within that cluster, where PGCT-1 301 
contained on average the earliest samples and PGCT-5 on average the latest samples. We compared 302 
the number of samples from all time points in only PGCT-1 and PGCT-5 to investigate associations 303 
between the MOM DSLNT threshold and gut microbiome development from the typically younger 304 
to the typically older PGCTs. Infants receiving MOM with DSLNT level below 241 nmol/mL had 305 
significantly more samples remaining within PGCT-1 throughout all time points (78% in PCGT-1 vs. 306 
22% in PGCT-5, χ2 test P <0.001), whereas infants receiving MOM with DSLNT above this threshold 307 
transitioned from PGCT-1 to PGCT-5 as demonstrated by a similar number of samples in each PGCT 308 
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across all time points (48% in PCGT-1 vs. 52% in PGCT-5, χ2 test P = 0.717). In addition to 309 
comparing samples from all times points, we next compared samples from the final time point only 310 
(i.e., DOL 50-60). After correcting for uneven frequency of sampling between groups, at the final 311 
time point infants receiving MOM above the DSLNT threshold were twice as likely to be in PGCT-312 
5 (3/11 samples below vs. 12/22 samples above DSLNT threshold; odds ratio 3.20, 95% CI 313 
0.6657 to 15.3819), which was characterised by high relative abundance of Bifidobacterium (figure 314 
4a). 315 
 316 
Explained variance and random forest classification of HMO and metagenome data  317 
Using the cross-sectional HMO and cross-sectional metagenome dataset, we sought to determine 318 
which clinical factors were most associated with the HMO and the bacterial profiles (figure 5a). 319 
Secretor status explained 56% of the variance within HMO profiles (adj. P < 0.001), but no other co-320 
variate was significantly associated with the HMO profiles. In contrast, the bacterial profiles were 321 
significantly associated with both postmenstrual age (R2 0.07; adj. P = 0.006) and day of life (R2 322 
0.07; adj. P = 0.006), as well as receipt of antibiotics at the time of sampling (R2 0.06; adj. P = 0.006) 323 
and receipt of probiotics (R2 0.12; adj. P = 0.006), but not maternal secretor status (R2 0.02; adj. P = 324 
0.58). Together, these findings highlight that HMO and bacterial profiles are influenced by numerous 325 
non-overlapping factors related to early life in preterm infants. 326 
We compared the performance of random forest classification models built on the cross-sectional 327 
subset of HMO profile data, metagenomic sequencing data, and the two datasets combined to classify 328 
an infant as NEC or healthy, given that all this information is available before onset of disease and 329 
could therefore function as a risk stratification system in clinical practice. The HMO profile alone 330 
had a classification error of 0.146, with 21% (3/14) NEC and 12% (4/34) control infants misclassified. 331 
DSLNT had the greatest contribution to classification with a Mean Decrease Accuracy (MDA) of 332 
0.11. Other HMOs contributing to classification accuracy included LNH (MDA = 0.012) and DFLNH 333 
(MDA = 0.011), which were non-significantly higher in NEC infants. Random forest generated using 334 
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the metagenomic sequencing data was characterised by a classification error of 0.229, with 43% 335 
(6/14) NEC and 15% (5/34) control infants misclassified. Enterobacter cloacae was the most 336 
important feature guiding the classification (MDA = 0.036), with higher relative abundance in NEC 337 
infants, followed by Bifidobacterium bifidum (MDA = 0.024) and Bifidobacterium longum (MDA = 338 
0.013) which had higher relative abundance in control infants. Combining HMO and metagenome 339 
datasets slightly improved the performance compared to using HMOs alone, with 21% (3/14) NEC 340 
infants and (9%) 3/34 controls misclassified. In this combined model, DSLNT was enriched in 341 
controls and DSLNH and the relative abundance of Escherichia unclassified were higher in NEC 342 
infants (figure 5b). 343 
 344 
Discussion 345 
Receipt of human breast milk and early life gut microbiome development are intrinsically linked and 346 
both influence the risk of NEC in preterm infants. Our study represents the largest analysis of HMOs 347 
in NEC and the first to integrate HMO and metagenome data. We found DSLNT was present in 348 
significantly lower concentrations in MOM fed to infants diagnosed with NEC. Furthermore, lower 349 
DSLNT concentrations in MOM were associated with reduced transition into PGCTs typically 350 
observed in older infants and lower relative abundance of Bifidobacterium spp.  351 
The HMO results from the current study build upon previous findings in humans, showing reduced 352 
DSLNT in MOM received by infants developing NEC, independent of maternal secretor status (17-353 
19). This is also supported by rodent studies where total and individual HMOs including 2’FL and 354 
DSLNT have shown a protective effect against NEC development (16, 36, 37). However, 2’FL and 355 
mixtures of HMOs (one of which included DSLNT) did not show any protection in NEC piglet 356 
models (38, 39). Importantly from a clinical perspective, in rats the protection provided by pooled 357 
HMOs could be reproduced with DSLNT alone, with specific dependence on its precise structure 358 
since closely related sialyllacto-N-tetraose (identical in structure to DSLNT but lacking one sialic 359 
acid residue) did not provide protection, suggesting a highly structure-specific mechanism (16). Our 360 
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findings further extend the evidence for the specificity of DSLNT in the NEC pathway. A threshold 361 
level of DSLNT (241 nmol/mL) from a single MOM sample correctly identified 91% of NEC infants 362 
(below threshold) and 86% of control healthy infants (above threshold).  Of the three infants who 363 
developed NEC despite a DSLNT above the threshold, two had not received MOM in the 3 weeks 364 
prior to disease onset and the remaining infant had a DSLNT concentration of 248 nmol/ml. 365 
Within the validation dataset (17), 100% NEC infants were correctly classified, but only 60% of 366 
controls. Making a robust diagnosis of NEC is difficult and it is possible that the specific threshold 367 
value of DSLNT we identified will have a different predictive value in other populations or where 368 
other criteria are used to determine the presence of disease. Our study contains a large number of 369 
cases coded clinically as NEC independently validated by blinded review. In addition, our cohort was 370 
more homogenous (predominantly white Caucasian) and the concentration of DSLNT less variable 371 
(current study IQR 184-321 nmol/mL vs. Autran et al. IQR 122-346 nmol/mL) despite using the same 372 
analytical platform. Given HMO composition and DSLNT concentrations may be influenced by 373 
genetic factors, geographical location, ethnicity (40), and seasonality (15), differential thresholds may 374 
improve diagnostic performance in other settings.  Taken together, this external validation and 375 
potential variation in DSLNT concentration by maternal factors underscore the need for large 376 
multicentre studies to both refine a universal or stratified threshold for DSLNT concentration in 377 
predicting NEC and potentially prospectively identifying milk samples that may benefit from 378 
supplementation with synthetically produced DSLNT. 379 
In addition to HMO profiles, our extensive longitudinal stool metagenomic analysis, represents one 380 
of the largest datasets to date. This extends our previous work (20, 33, 41) where DMM was used to 381 
facilitate analysis of temporal microbiome development, and integrate the HMO DSLNT threshold 382 
of 241 nmol/ml with infant gut microbiome profiles. We observed a difference in microbiome 383 
development between DSLNT groups, with infants receiving MOM with lower DSLNT tending to 384 
have delayed progression into the PGCT typically expected in older infants (i.e., PGCT-5). This 385 
supports the theory that concentrations of specific HMOs in MOM are associated with differences in 386 
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gut microbiome development. On the contrary, transition into PGCT-5 was twice as likely in infants 387 
receiving MOM with DSLNT above the threshold, which was characterised by high relative 388 
abundance of Bifidobacterium spp. Bifidobacterium has previously been linked to health in preterm 389 
infants (20, 41, 42) and our current findings in pre-NEC samples further support the association of 390 
reduced Bifidobacterium spp., specifically Bifidobacterium longum, as a risk factor for NEC. In 391 
addition, our species level metagenome data advanced previous associations of Enterobacteriaceae 392 
with NEC (21, 23, 43), showing E. cloacae relative abundance was higher before NEC.  393 
Random forest analysis confirmed the capability of HMO profiles to identify infants who developed 394 
NEC and slightly outperformed metagenome profiles by correctly classifying three more NEC cases 395 
and one more control. Combining HMO and metagenome data before disease accurately classified 396 
87.5% of infants as healthy or NEC, with DSLNT and the bacterial species identified as important in 397 
the random forest analysis being comparable to the unsupervised analysis in the current study and in 398 
previous studies. Further work is needed to determine if DSLNT functions via modulation of the 399 
microbiome or by acting directly on the host, such as acting in a structure-specific receptor-mediated 400 
way to alter immune functioning and reduce inflammation leading to necrosis. In the event of the 401 
latter, a microbial community with less DSLNT utilisation could provide an advantage to reducing 402 
NEC risk. Taken together, the current findings and recent work highlighting the ability of 403 
Bifidobacterium spp. to utilise HMOs is strain specific (7, 8) underscore the need for further research 404 
to better understand the complexity of human milk and other nutritional exposures, including the use 405 
of supplements such as prebiotics and probiotics in preterm infants. In addition to therapeutics, the 406 
classifiers may provide a basis for the development of biomarkers predicting NEC risk. While 407 
additional work is needed, the addition of microbial biomarkers may allow for the most accurate 408 
predictions and could inform NEC risk for infants where MOM (and thus HMO information) is not 409 
available. 410 
This study involved the largest cohort to date investigating the relationship between HMO 411 
composition and NEC development, and includes one of the most extensive longitudinal stool 412 
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metagenomic analyses of preterm infants. However, there are several limitations and avenues for 413 
future work. First, the cross-sectional HMO profiling data precluded assessment of changes within 414 
mothers over time and how this may relate to NEC development. The milk sample was selected based 415 
on the day of infant feeding and the actual expression of milk may have occurred several days earlier, 416 
which may be important clinically.  Current published data suggest that the concentration of HMOs, 417 
including DSLNT, are relatively stable over time (14), but validation in longitudinal preterm cohorts 418 
is needed. Second, the amount of MOM an infant receives and tolerates each day is variable, and 419 
DSLNT exposure is dependent on both concentration and volume. Although this study identifies 420 
DSLNT concentration alone may be useful from both a diagnostic and therapeutic perspective, further 421 
studies could consider the volume of milk received in addition to concentration. Thirdly, inclusion of 422 
metagenome data was opportunistic based on available data and cost prohibited sequencing all infants 423 
in the cohort. As such, the classification accuracy of the model might be impacted by the reduced 424 
sample size in comparison to the full cohort, necessitating the need for follow-up analyses in larger 425 
cohorts. Despite this, the sample size of 644 including 195 samples from 14 preterm infants who 426 
developed NEC makes this dataset one of the largest published to date. Finally, the gene relative 427 
abundance data warrants further investigation, in combination with other experimental approaches, 428 
to help inform the HMO utilisation capacity of different strains. 429 
In summary, HMO profiling of MOM coupled to metagenomic sequencing of preterm stool showed 430 
that the concentration of a single HMO, DSLNT, was lower in milk received by infants who 431 
developed NEC. The lower concentration of DSLNT was associated with altered microbiome 432 
development, specifically a reduced progression toward the PGCT typically found in the older infants 433 
which was abundant in Bifidobacterium spp. These results suggest MOM HMO profiling may provide 434 
potential targets for biomarker development and disease risk stratification. They may also guide 435 
focussed donor milk use (e.g., prioritise high DSLNT for preterm infants) and novel avenues for 436 
supplements that may prevent life-threatening disease. 437 
  438 
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Tables 572 
Table 1. Demographics of the analytical cohort with human milk oligosaccharide profile data. 573 
Differences between groups were tested applying Chi-square test and Dunn’s post-hoc test where 574 
applicable. 575 
 Control NEC P value 
Number of patients 37 33 - 
Secretors 25 (68%) 20 (61%) 0.544 
Male 14 (38%) 22 (67%) 0.016 
Vaginal delivery 25 (68%) 17 (52%) 0.171 
Gestational age  25 [24; 26] 25 [24; 27] 0.881 
Birthweight 670 [585; 830] 670 [600; 840] 1.000 
Probiotics ever 37 (100%) 31 (94%) 0.855 
MOM only 3 (8%) 6 (18%) 
0.468 
MOM + Formula  11 (30%) 12 (37%) 
MOM + BMF 10 (27%) 7 (21%) 
MOM + Formula + BMF 13 (35%) 8 (24%) 
DOL breast milk sample 18 [12; 31] 18 [13; 34] 0.636 
DOL disease onset - 19 [14; 35] - 
NEC surgical - 16 - 
NEC, necrotising enterocolitis; MOM, mother’s own breast milk; BMF, breast milk fortifier; 576 
DOL, day of life 577 
 578 
 579 
 580 
Figure Legends 581 
  582 
Figure 1. Analysis of human milk oligosaccharide (HMO) profiles and DSLNT concentration 583 
in necrotising enterocolitis (NEC) and controls. a, Orthogonal partial least squares discriminant 584 
analysis (OPLS-DA) of maternal HMO profiles fed to infants diagnosed with NEC and controls. The 585 
P value was calculated based on 2000 permutations. b, Visual representation of P values obtained 586 
from comparison of individual HMOs between NEC and control group. Wilcoxon rank sum test was 587 
applied, and P values adjusted with FDR algorithm. The line indicates P value = 0.05. c, Univariate 588 
receiver operating characteristic (ROC) curve generated on DSLNT concentration identified 241 589 
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nmol/ml as the best threshold for NEC prediction. The performance of the classification is defined 590 
by the area under the curve, specificity (false positive rate) and sensitivity (false negative rate). d, 591 
Box plot showing the concentration of disialyllacto-N-tetraose (DSLNT) between NEC and controls. 592 
Blue line represents the 241 nmol/ml threshold. 593 
 594 
Figure 2. Analysis of human milk oligosaccharide (HMO) profiles with stratification of 595 
necrotising enterocolitis (NEC) into medical (NEC-M) and surgical (NEC-S). a, Partial least 596 
squares discriminant analysis (PLS-DA) of HMO profiles from control, NEC-M, and NEC-S infants. 597 
NEC-M and NEC-S cluster together and separately from controls (P < 0.001). P values were 598 
calculated based on 2000 permutations. Box plots of (b) disialyllacto-N-tetraose (DSLNT) and (c) 599 
lacto-N-neotetraose (LNnT) concentration between control, NEC-M, and NEC-S infants. Kruskal-600 
Wallis followed by Dunn’s test using Bonferroni adjustment was applied. d, Adjusted linear 601 
regression model for DSLNT and LNnT including potential clinical confounders. P values were 602 
corrected by FDR. Significant variables are indicated by asterisks: *** denotes FDR P < 0.001; ** 603 
denotes FDR P > 0.01. DOL, day of life; PMA post-menstrual age; GA, gestational age. 604 
 605 
Figure 3. Cross-sectional analysis of preterm stool metagenome profiles between necrotising 606 
enterocolitis (NEC) and matched controls. Analysis includes the sample closest NEC onset 607 
(median of 3 days prior to NEC) and a corresponding control sample matched by day of life. a, Alpha-608 
diversity based on observed species (richness) and Shannon diversity. b, Bray-Curtis principal 609 
coordinate analysis. c, Box plots showing the relative abundance of significant phyla. d, Box plots 610 
showing the relative abundance of significant species. 611 
 612 
Figure 4. Analysis of preterm gut community types (PGCTs) by infants receiving maternal milk 613 
above or below the 241 nmol/mL DSLNT threshold. The entire dataset of 644 samples formed five 614 
distinct clusters based on lowest Laplace approximation following Dirichlet multinomial 615 
clustering. a, Heatmap showing the relative abundance of dominant bacterial species within each 616 
PGCT cluster. The phyla for each species are also shown. b, Transition model showing the 617 
progression of samples through each PGCT, from day of life 0 to 60 across eight distinct time points. 618 
Plots are separated based on whether the concentration of disialyllacto-N-tetraose (DSLNT) in 619 
maternal milk was above or below the 241 nmol/mL threshold. Nodes and edges are sized based on 620 
the total counts. Nodes are coloured according to DMM cluster number and edges are coloured by 621 
the transition frequency. Transitions with less than 5% frequency are not shown. 622 
 623 
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Figure 5. Modelling of cross-sectional human milk oligosaccharide (HMO) and infant stool 624 
metagenomic profiles using Adonis and random forest. a, horizontal bar plots showing the 625 
variance (r2) in maternal HMO and infant stool metagenomic profiles explained by clinical covariates 626 
as modelled by univariate Adonis. Variables with an FDR P < 0.05 are shown in red. DOL, day of 627 
life; PMA, post-menstrual age. b, Feature importance from combined HMO and metagenome random 628 
forest classification model. Mean decrease accuracy (MDA) value defines the contribution given by 629 
a certain feature to classification process. 630 
631 
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Online supplementary figure Legends 632 
 633 
Online supplementary figure 1. Sampling schematic for the entire cohort. Only samples collected 634 
in the first 100 days of life are shown. Shapes represent sample timing in relation to the diagnosis of 635 
disease; control (n = 37) and necrotising enterocolitis (NEC; n = 33). Colours indicate if the sample 636 
on that day of life was a maternal breast milk human milk oligosaccharide (HMO) or infants stool 637 
metagenome, or if both sample/data types were generated from each sample collected on that day. 638 
 639 
Online supplementary figure 2. Comparison of human milk oligosaccharide (HMO) profiles by 640 
maternal secretor status. All infants were included (n = 77). a, Principal component analysis (PCA) 641 
showing the clustering of HMO profiles based on secretor status. b, Visual representation of P values 642 
for comparison of individual HMOs between secretor and non-secretor groups. 16 of the 19 HMOs 643 
were different between the two groups. Wilcoxon rank test was applied, and P values were adjusted 644 
using FDR algorithm. c, HMO Shannon diversity was higher in breast milk from secretor mothers 645 
compared to non-secretors. Wilcoxon rank test was applied. d, Stacked bar plot of HMOs 646 
concentrations describing HMO profile of each breast milk sample analysed. 2’FL used for 647 
identifying secretor status is almost absent in non-secretor breast milks, and present in relatively high 648 
concentration in samples from secretor mothers. 649 
 650 
Online supplementary figure 3. Human milk oligosaccharide (HMO) profiles and disialyllacto-651 
N-tetraose (DSLNT) are different between necrotising enterocolitis (NEC) and control group 652 
independent of maternal secretor status. Orthogonal partial least squares discriminant analysis 653 
(OPLS-DA) of breast milk HMO profiles from secretors (a) and non-secretors (b). P values were 654 
calculated performing 2000 permutations. Comparison of DSLNT concentration in milk received by 655 
NEC or controls separated by (c) secretor and (d) non secretor status. DSLNT concentration is lower 656 
in milk received by the NEC group independently of secretor status. Group comparison was 657 
performed applying Wilcoxon rank test and P values adjusted using FDR.  658 
 659 
 660 
Online supplementary figure 4. Shannon diversity of human milk oligosaccharides (HMOs) 661 
was not associated with NEC development. Shannon diversity of (a) overall cohort, (b) secretor 662 
group, and (c) non-secretor group.  663 
 664 
 665 
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Online supplementary figure 5. Human milk oligosaccharide (HMO) profiles were predictive 666 
of necrotising enterocolitis (NEC) status. a, Receiver operating characteristic (ROC) curves 667 
generated using linear support vector machine (SVM) classification of HMO profiles between NEC 668 
and control groups. Increasing numbers of HMO were included in the model and performance was 669 
described by the AUC. Two HMOs model gave the optimal performance. b, Feature importance for 670 
the two HMOs model. Disialyllacto-N-tetraose (DSLNT) was selected as discriminatory feature in 671 
100% of the permutations. c, Box plot showing the concentration of disialyllacto-N-tetraose 672 
(DSLNT) between NEC and controls from the validation dataset, Autran et al. (2018). Blue line 673 
represents the 241 nmol/ml threshold. 674 
 675 
 676 
Online supplementary figure 6. Disialyllacto-N-tetraose (DSLNT) and lacto-N-neotetraose 677 
(LNnT) concentrations were not influenced by the day of life (DOL) of sample. Plot of (a) 678 
DSLNT and (b) LNnT concentrations in relation to DOL of the sample. P values were calculated by 679 
linear regression and DSLNT and LNnT concentrations were not related to the DOL the breast milk 680 
was fed to the infant.  681 
 682 
